Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have a BMI of greater than or equal to ≥27 kg/m² and \<less than 35 kg/m² with at least 2 obesity-related health problems or ≥35 kg/m² with at least 1 obesity-related health problems. Health problems are IGT, hyperlipidemia, or NAFLD.~* Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.~Exclusion Criteria:~* Have diabetes.~* Acute or chronic liver disease other than NAFLD.~* Have a self-reported change in body weight \>5 kg within 3 months prior to screening.~* Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months.~* Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2, calculated by Japanese Society of Nephrology coefficient-modified Chronic Kidney Disease-Epidemiology equation during screening.~* Have a known clinically significant gastric emptying abnormality.~* Have had a history of chronic or acute pancreatitis.~* Have thyroid-stimulating hormone outside of the range of 0.4 to 6.0 micro units per milliliter (μIU/mL) at screening.~* Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity.~* Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder within the last 2 years.~* Have a cardiovascular condition within 3 months prior to randomization~* Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome type 2.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 Milligrams (mg) Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo administered SC QW.

Based on this trial design, predict the completion outcome and termination type (if applicable).